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This thesis describes the synthesis of two peptidomimetics that contain heterocyclic 
phosphate group mimics.  These compounds are based on a potent STAT3 inhibitor and 
therefore have the potential of being SH2 domain ligands.  Due to problems with the purification 
of the final products, the mimetic containing the isothiazolidinone (IZD) moiety was obtained as 
the major component of a mixture in < 90% purity and the 5,6-dihydro-2H-1,2,6-thiadiazine 1,1-
dioxide (TDA) analog was isolated as the major component of a mixture in < 90% purity based 
on NMR analyses. 
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1.0  INTRODUCTION AND BACKGROUND INFORMATION 
1.1 PHOSPHATE GROUP MIMICS 
Due to the activity of phosphorylated proteins in nature and the poor bioavailability of 
phosphorylated pharmaceutical compounds, many phosphate group mimics have been developed 
for the ubiquitous phosphotyrosine moiety.1-3  One strategy towards creating these mimics has 
been to stabilize the compound against the phosphatases present in cells.  To accomplish this, the 
oxygen linker present between the phosphate and the aromatic ring was replaced with a 
methylene group to create the phosphinomethylphenylalanine (Pmp) moiety (Figure 1-1a).4  This 
small change has been shown to increase the stability of the phosphate group towards enzymatic 
cleavage, but it also reduced binding ability towards the desired targets.2,5  This has been 
rationalized to be a consequence of an increase in the pKa of the phosphonate group at 
physiological pH from 5.7 for the phosphotyrosyl group to a value of 7.1 for the Pmp group.5  
This change in pH results in a reduction of the formal negative charge of – 2 for the fully 
deprotonated phosphotyrosyl group versus a – 1.5 for the Pmp group that is in equilibrium 
between its mono-protonated and unprotonated states.  To remedy this problem, the methylene 
linker was fluorinated to create the F2Pmp phosphotyrosine mimic (Figure 1-1a), which restored 
the binding affinity to the levels of the parent compound.6-8 
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Figure 1-1. Common phosphotyrosine mimics. 
 
While these groups have been resistant to enzymatic cleavage, they still have poor 
membrane transport properties.2,3,9  Switching from a phosphate-based mimic to a carboxylate 
group has led to the 2-(oxalylamino)-benzoic acid (OBA) (Figure 1-1b),10-13 3-carboxy-4-
carboxymethyloxyphenylalanine (CMS) (Figure 1-1c),14-16 and p-malonylphenylalanine (Pmf) 
(Figure 1-1d)17,18 groups.  These groups have better membrane permeability and have been used 
successfully in high affinity binding molecules. 
An alternate approach to making a cell permeable inhibitor is to use compounds with a 
high number of hydrogen bond accepters while keeping the molecule either neutral or mono-
ionic at physiological pH.  This strategy allows for the strong electrostatic element of the di-
anionic phosphate group to be mimicked while still allowing the inhibitor to pass through the cell 
membranes.  Researchers at AstraZeneca published that thiadiazolidinone 1-1 is an inhibitor of 
protein tyrosine phosphatase-1B (PTP1B) (Figure 1-2).19  This compound had an IC50 value of 
2.47 µM.  A tetronic acid moiety has also been used as a phosphate mimic in compound 1-2 to 
inhibit the VH-1 related (VHR) and Cdc25B protein phosphatases with IC50 values of 11.6 µM 
and 2.2 µM, respectively.20  Sugen, Inc. utilized the trifluoromethyl sulfonyl group in ether 1-3 
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as a phosphate mimic to inhibit a range of PTPs in the µM range and thus obtained one of the 
first uncharged mimics to show substrate-competitive inhibition.21 
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Figure 1-2. Miscellaneous phosphate group mimics. 
 
The Incyte Corporation developed isothiazolidinone (IZD) as a phosphate mimic using a 
structure-based design and then incorporated it into a series of PTP1B inhibitors (Table 1-1).22  
The unsaturated 1-4, along with (S)-IZD 1-5 was active against PTP1B with IC50 values of 3000 
nM and 190 nM, respectively.  The (R)- derivative (1-6) was found to be more than five times 
less active than the unsaturated IZD 1-4, and more than eighty times less active than its epimer.  
The (S)-IZD (1-5) was also found to be ten times more potent than the corresponding inhibitor 
containing the F2Pmp peptide mimic (1-7). 
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Table 1-1. Comparison of the IZD stereoisomers. 
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a PNPP enzyme assay. 
 
Shortly after publishing the initial IZD paper, the Incyte Corporation published non-
peptidic inhibitors 1-8 and 1-9 (Figure 1-3).23,24  These compounds were shown to have IC50 
values of 35 nM and 480 nM, respectively, against PTP1B, but, more importantly, were found to 
be cell permeable in the caco-2 adenocarcinoma cell line.24 
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Figure 1-3. Cell permeable IZD containing PTP1B inhibitors. 
 
The structurally analogous 5,6-dihydro-2H-1,2,6-thiadizine 1,1-dioxide (TDA) moiety 
was targeted by the Wipf group as phosphate group mimic based on other biologically active 
compounds that contain the sulfamide group.19,25,26  Prior to our work, the procedures to 
synthesize this moiety involved either the condensation of sulfamide with a 1,3-dicarbonyl 
compound (Scheme 1-1, equation a) or the condensation of an arylidenesulfamide and ethyl 3,3-
diethoxypropionate (Scheme 1-1, equation b).27-31 
 
 
 
 
Scheme 1-1. Synthetic strategies towards the thiadiazine moiety. 
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Our initial work found that the processes outlined in Scheme 1-1 were unreliable 
(unpublished data).  During optimization studies, it was found that sulfamide (1-10) and ethyl 
3,3-diethoxypropionate (1-14) could be condensed to form the eight-membered dimer 1-16 in 
good yields (Scheme 1-2).  A suspension of dimer 1-16 in CH2Cl2 could then be condensed with 
a variety of aldehydes using ten equivalents of TFA to provide compounds of type 1-17 with 
improved reaction times and with yields ranging from 23–74 %. 
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Scheme 1-2. Wipf group strategy for constructing the thiadiazine moiety. 
 
The TDA moiety has four points that allow for diversification (Figure 1-4a).  The R1 
position can be by varied by condensing different aldehydes with dimer 1-16.  Both alkyl and 
aryl substituents have been included into this position. 
Initial attempts at selective N-alkylation using standard SN2 conditions provided mixtures 
of addition at both R2 and R3 sites.  Switching to Mitsunobu reaction conditions allowed for the 
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selective alkylation at R2  (Figure 1-4b).32  This allows for the incorporation of alkyl, benzyl, 
allylic and propargylic side chains. 
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Figure 1-4. Points of elaboration of the TDA moiety. 
 
 Once the R2 position has been occupied, the R3 position can be readily alkylated (Figure 
1-4c).32  This has allowed for the incorporation of alkyl, benzylic and side chains containing 
pyridine rings.  Varying amounts of halogenation on the benzyl rings is well tolerated. 
The R4 position has been saponified to the acid (Figure 1-4d).33  This position could be 
amenable towards further functionalization through Curtius rearrangements, decarboxylation, or 
amidation and current efforts in the group are focused on the realization of these transformations. 
The TDA group has also been shown to be stable towards palladium catalyzed cross 
coupling (Scheme 1-3).34  TDA derivative 1-18 was coupled with boronic acid 1-19 to afford 
diaryl 1-20 in 43% yield.  These elaborations allow for the possibility of the TDA moiety to be 
incorporated into many different types of scaffolds. 
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Scheme 1-3. Suzuki coupling with TDA coupling partner. 
 
As a proof of concept, a dipeptide corresponding to the series of PTP1B inhibitors 
synthesized in the development of the IZD group (1-4 through 1-7) was prepared.22,35  Boc 
protection of L-tyrosinamide followed by triflation of the phenol afforded 1-22 (Scheme 1-4).  
Stille coupling with tributyl(vinyl)tin and subsequent Boc deprotection gave vinyl derivative 1-
23 in 63% over four steps. 
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Scheme 1-4. Synthesis of vinyl derivative 1-23. 
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Peptide coupling with Fmoc protected phenylalanine followed by Johnson-Lemieux 
cleavage of the olefin afforded aldehyde 1-24 (Scheme 1-5).  A protecting group switch to the 
acetyl group gave 1-25, which was then treated with 1-16 to give dipeptide 1-26 in 40% yield.  
The peptide was found to be active against MKP-1 and MKP-3 phosphatases. 
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Scheme 1-5. Formation of dipeptide 1-26. 
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1.2 SH2 OVERVIEW  
Src homology 2 (SH2) regions were originally discovered in the Src family of protein-
tyrosine kinases (PTK) and have subsequently been found to be present in 110 separate 
proteins.36  These regions are approximately 100 amino acids long, highly conserved domains 
involved in cellular signal transduction.37-40  They specifically bind to peptide sequences 
containing a phosphotyrosine (pTyr) moiety and, along with PTK and protein-tyrosine 
phosphatases (PTP), provide the framework for cell signaling.39,41  The peptide complex formed 
from the coordination between the phosphorylated protein and its corresponding SH2 domain 
containing ligand acts to modulate a variety of cellular processes including altering gene 
expression, regulating kinase activity, and inducing ubiquitination.42-44  Not surprisingly, this 
requires a high level of specificity between the phosphorylated sequence and its corresponding 
SH2 domain partner to access the correct cellular function.  SH2 domains have been found to be 
very sensitive towards subtle changes in the residues immediately following the pTyr group and 
examination of the binding affinity of many short phosphopeptide sequences across a range of 
SH2 domains has been studied.45,46 
1.3 STAT3: MECHANISM OF ACTION AND INHIBITION 
The mammalian STAT protein family consists of seven members (STAT1, STAT2, 
STAT3, STAT4, STAT5a, STAT5b, STAT6) and share six conserved structural domains.47-50  
These domains are the amino terminal domain, the coiled-coil domain, the DNA binding domain, 
a linker domain, the SH2 domain, and a transcriptional activation domain (Figure 1-5). 
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Terminal Coiled-Coil DNA Binding Linker SH2 TAD
P
 
 
Figure 1-5.  The conserved domains of the STAT family of proteins. 
 
The transcriptional activation domain is the most divergent of the domains and is the 
main contributor to the specificity of the individual STATs.51-56  A smaller set of STAT proteins 
are also present in primitive eukaryotes and each of those STAT proteins are tied to multiple 
signaling pathways.57-59  This points to STATs 3 and 5 being the first mammalian STAT proteins 
to evolve as they show the greatest pleiotropy of the family in humans. 
STATs 1 and 2 can form homo and heterodimers and predominantly transduce signals for 
type I and type II interferons (IFN).60,61  Knockout studies have shown that STAT1 is important 
in IFN-dependant immune responses in both viral and microbial agents.  Using knockout studies 
with STAT2-deficient mice has implicated it in the type I IFN signaling pathway.62  STAT2 is 
the only STAT not known to bind to growth arrest-specific (GAS) genes following its activation. 
The expression of STAT4 is limited to NK cells, dendritic cells, and T lymphocytes.  
STAT4 was shown to be activated by IL-12, which plays an essential role in the development of 
Th1 subset of T cells.63,64  Knockout studies confirmed this connection.65,66 
STATs 5a and 5b are encoded by linked genes and are expressed in all tissue types.67  
They are activated by a host of proteins including the IL-2 and IL-3 families, growth hormone, 
prolactin and EPO and TPO.68,69  Knockout studies show that despite sharing 96% of their 
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sequence, STATs 5a and 5b show distinct phenotypes.50,67  STAT5a knockout mice showed the 
PRL dependant mammary gland to be defective in its development.70,71  The STAT5b knockout 
mice showed traits similar to growth hormone receptor deficient mice.71,72  As high levels of 
growth hormone found in males activate STAT5b, the deletion of this protein affected the males 
more than the females.  The male knockout mice had much more female physical characteristics 
and an altered expression of gender specific genes to favor the female variant.  It is believed that 
each of the STAT5 proteins can partially substitute for the other as double knockout mice have 
the combined phenotypes of the individual knockouts, only more severe in each.72 
STAT6 knockout mice have been found to be defective in their ability to produce the Th2 
subset of helper T cells.73-75  It also has been found to be a part of the IL-4 signaling pathway as 
tissues from STAT6 knockout mice were stimulated with IL-4, the tissue failed to upregulate the 
expression of the MHC class II, IL-4R, and low affinity IgE receptors. 
The STAT3 protein contributes to many different cellular processes including promoting 
cell growth, maintaining an undifferentiated state of embryonic stem cells, inhibiting IL-6 
induced neuronal differentiation in PC12 cells, and mediating cytokine induced terminal 
differentiation in a variety of cell types.76-84  Constitutive STAT3 activity has also been 
implicated in a wide range of cancers and has made targeting this protein attractive for cancer 
therapies.85-89 
The overall STAT signaling cascade is very similar for all of the proteins of the family.  
It begins with an extracellular ligand binding to a transmembrane protein that, in turn, activates 
the intercellular Janus kinase (JAK) (Figure 1-5).90,91  The JAK protein then phosphorylates in 
the SH2 domain of STAT, which instigates dissociation from the JAK protein complex.92,93  The 
phosphorylated monomer then undergoes dimerization through reciprocal phosphotyrosine-SH2 
 13 
interactions.42,47,48,94  The dimer then binds to the either transport protein importin α5 or α7 and 
translocates the complex to the nucleus where it attaches to the DNA and begins transcription.95-
97  The only gene that a STAT protein is known to directly transcribe is VEGF but it they are 
believed to activate the BCL-XL, MCL1, survivin, MYC, and the cyclin D1 and D2 genes.98-109  
At an unknown point during this pathway, a serine residue is also phosphorylated and it is 
believed that it assists in the binding of the STAT dimer to DNA.55,110-113 
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Figure 1-6. General STAT protein cellular mechanism. 
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Targeting the SH2 domain of STAT3 to disrupt dimerization to block the mechanism 
prior to the translocation to the nucleus has been described as one of the major strategies towards 
STAT inhibition.89  It has been shown that dimerization of the protein is required for nuclear 
translocation and DNA binding.47,48,92,93,95  It is also known that mutations on the protein 
designed to prevent dimerization halt gene transcription associated with that particular STAT 
protein.95 
STAT3 activity can be disrupted using SH2 domain-binding peptide 1-27 (Figure 1-6).114  
This hexamer was found to inhibit DNA binding with a DB50 value of 235 µM.  Scanning for the 
essential amino acid elements in the peptide revealed two strongly binding tripeptides: Pro-pTyr-
Leu (1-28) and Ala-pTyr-Leu (1-29) with DB50 values of 182 µM and 217 µM, respectively.  All 
three of these active peptide sequences were rendered inactive when the phosphate group was 
removed from the molecule.  These sequences were also found to inhibit STAT3 selectively over 
STAT1 and STAT5. 
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Figure 1-7. Potent STAT3 DNA binding inhibitor 1-27 and the high affinity binding tripeptides 
derived from it. 
 
It was known early in the history of the STAT proteins that the cytoplasmic domain of 
the protein gp130 was able to bind to the SH2 region of STAT3.115  Scanning of the gp130 
domain showed that it bound to the SH2 region with a pTyr-Xxx-Xxx-Gln motif.  This type of 
“two prongs – two hole” motif is general for binding to the SH2 domains in a variety of 
proteins.46,87  In 2003, gp130 was used as a template to derive peptide (1-30), which had an IC50 
value of 150 nM against STAT3 binding to DNA (Figure 1-7).116 
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Figure 1-8. Highly potent STAT3 inhibitor 1-30 derived from gp130 and the peptidomimetics 1-
31 and 1-32. 
 
Further derivatization of peptide 1-30 led to the discovery of compound 1-31, which was 
found to bind to STAT3 with a Ki = 190 nM (Figure 1-7).117  The key component to this 
compound appears to be the Freidinger lactam segment since reducing the ring size from a 
seven-membered ring to a six-membered ring (1-32) caused the potency to drop significantly to 
Ki = 3.13 µM.118  
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2.0  SYNTHESIS OF TWO POTENTIAL SH2 DOMAIN LIGANDS CONTAINING 
PHOSPHATE GROUP MIMICS 
2.1 TARGET SELECTION 
Due to the nanomolar activity of 1-31 and the general low bioavailability of 
phosphorylated derivates, we undertook the task to replace the phosphate group with mimics 
that, while still polar, are not strongly ionic and would increase the activity of the compound 
along with raising its bioavailability.  With the choice of both IZD and TDA phosphotyrosine 
replacements, our target molecules became compounds 2-1 and 2-2, respectively (Figure 2-1). 
 
HN
R
O
N
O
N
H
O
N
H
O
H
N
O NH2
S
NH
O
O O
H
N S
NHEtO2C
O
O
2-1 R =
2-2 R =
OO
 
 
Figure 2-1. Peptidomimetic targets. 
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2.2 RETROSYNTETIC ANALYSIS 
The retrosynthetic analysis of target 2-3 began with cleaving the amide bonds to reveal 
the amino acid subunits.  Since the two targets are differentiated by the substitution on the 
tyrosine residue, it would be desirable for that to be the last bond to form.  This would reveal the 
modified tyrosine acid 2-4 and Freidinger lactam 2-5 as coupling partners (Scheme 2-1). 
 
CbzHN
Het
O
N
O
N
H
O
N
H
O
NHBn
O NH2
N
O
H2N
O
N
H
O
NHBn
O NHP
CbzHN
Het
O
OH
2-3 2-4 2-5  
 
Scheme 2-1. Retrosynthetic analysis of initial bond disconnection. 
 
The tripeptide 2-5 could be formed from a peptide coupling of the suitably protected ε-
lactam 2-6 and glutamine derivative 2-7 (Scheme 2-2).  Lactam 2-6 could, in turn, be created 
from the alkylation of the of commerically available lactam (2-8) with methyl bromoacetate (2-
9).  Glutamine derivative 2-7 could result from the amidation of protected glutamine (2-10) with 
benzyl amine (2-11). 
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Scheme 2-2. Retrosynthetic analysis of tripeptide 2-5. 
 
Turning to the tyrosine subunits, IZD-tyrosine derivative 2-12 could be realized by a 
Suzuki-Miyaura cross-coupling of boronic acid 2-13 and the known IZD coupling partner 2-14 
(Scheme 2-3).22  Boronic acid 2-13 could be formed from iodide 2-15, which would result from 
iodination of L-phenylalanine (2-16). 
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Scheme 2-3. Retrosynthetic analysis of the IZD phosphotyrosine mimic. 
 
TDA-tyrosine derivative 2-17 could be the result of a condensation of aldehyde 2-18 and 
the eight-membered heterocycle 1-16 (Scheme 2-4).  Aldehyde 2-18 could be formed from the 
oxidative cleavage of olefin 2-19.  Olefin 2-19 could be formed by a Stille reaction of a vinyl 
stannane and triflate 2-20, which could be derived from L-tyrosine (2-21). 
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Scheme 2-4. Retrosynthetic analysis of the TDA phosphotyrosine mimic. 
2.3 SYNTHESIS OF FREIDINGER LACTAM FRAGMENT 
Commercially available protected glutamate (2-22) was coupled with benzyl amine (2-
11) to form benzyl amide 2-23, which was used directly in the next step (Scheme 2-5).  
Treatment with diethylamine afforded free amine 2-24 in 91% over two steps. 
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Scheme 2-5. Synthesis of glutamine derivative 2-24. 
 
Commercially available Boc-Lys(Cbz)-OH (2-25) was treated with N-
hydroxysuccinimide in the presence of EDCI to afford Boc-Lys(Cbz)-OSu (Scheme 2-6).  This 
compound was immediately subjected to hydrogenation with 10% Pd/C in ethyl acetate under a 
hydrogen atmosphere to deprotect the Cbz group, and the resulting amino acid spontaneously 
underwent ring closing to form caprolactam 2-26 in variable yields.  The amide nitrogen was 
then alkylated with methyl bromoacetate to afford compound 2-27 in 63% yield (quantitative 
yield based on recovered starting material). 
 
BocHN OH
O
NHCbz
1. SuOH, EDCI,
EtOAc
2. Pd/C, H2, 
EtOAc
7 - 42% (2 steps)
NH
BocHN
O
Methyl
bromoacetate (2-9),
NaH
 MeCN
63% 
(quant. BRSM)
N
O
BocHN OMe
O
2-25
2-26 2-27
 
 
Scheme 2-6. Synthesis of methyl ester 2-27 from bis-protected lysine 2-25. 
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Due the poor yields obtained for lactam 2-26, we switched the starting material to the 
commercially available L-(-)-α-amino-caprolactam hydrochloride (2-28) (Scheme 2-7).  Boc 
protection of the amine followed by amide alkylation with methyl bromoacetate (2-9) afforded ε-
lactam 2-27 in 98% yield over two steps 
 
N
O
BocHN OMe
O
NH
O
H2N
1. Boc2O, Et3N,
THF/H2O
2. Methyl bromoacetate (2-9),
NaH, MeCN
98% (2 steps)
HCl •
2-28 2-27  
 
Scheme 2-7. Elaboration of caprolactam 2-28 into methyl ester 2-27. 
 
With these two coupling partners in hand, it was possible to hydrolyze methyl ester 2-27 
and couple it to amine 2-24 with EDCI and HOBt to afford tripeptide 2-29 in 82% yield over two 
steps (Scheme 2-8). 
 
N
O
BocHN OMe
O 1. LiOH, dioxane/H2O
2. 2-24 EDCI, HOBt,
 DIPEA. CH2Cl2
82% (2 steps)
N
O
BocHN
O
N
H O
NHBn
O NHTrt
2-292-27  
 
Scheme 2-8. Synthesis of Boc protected tripeptide 2-29. 
 
Selective deprotection of the Boc protecting group in the presence of the trityl group to 
arrive at amine 2-30 was unsuccessful (Table 2-1). Treatment with HCl in dioxanes resulted in 
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the rapid loss of the trityl group (Table 2-1, entry 1) and buffered TMS triflate resulted in a 
compound with an incorrect mass by LCMS (Table 2-1, entry 2).  Microwave conditions to 
remove the Boc group resulted in complete recovery of the starting material at both 180 °C and 
250 °C (Table 2-1, entries 3 and 4 respectively).  An attempt to use B-bromocatechol borane 
resulted in an unidentified compound that was not the desired product (Table 2-1, entry 5). 
 
Table 2-1. Attempts at finding selective Boc deprotection conditions. 
 
N
O
H2N
O
N
H O
NHBn
O NHTrt
N
O
BocHN
O
N
H O
NHBn
O NHTrt
conditions
HCl, dioxane
TMSOTf, 2,6-lutidine, CH2Cl2
µW 180°C, o-DCB
µW 250°C, o-DCB
                  0°C to rt, MeCNO
B
O
Br
loss of trityl group
incorrect mass by LCMS
no reaction
no reaction
unidentifiable material
1
2
3
4
5
entry conditons results
2-29 2-30
 
 
Due to the lack of orthogonality between the Boc and trityl group, a protecting group 
switch was required (Scheme 2-9).  Lactam 2-27 was subjected to a three-step sequence of 
saponification, Boc deprotection, and Fmoc protection to afford Fmoc derivative 2-31.  The 
crude acid was then coupled to amine 2-24 with T3P119-121 to give tripeptide 2-32 in 77% yield 
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over four steps.  Removal of the Fmoc group proceeded smoothly to afford amine 2-30 which 
provided a compound ready for coupling with the phospho-mimetic tyrosine derivatives. 
 
1. LiOH,THF/H2O
2. HCl, dioxane
3. Fmoc-OSu, Na2CO3
dioxane/H2O
N
O
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CH2Cl2
77% (4 steps)
Et2NH
MeCN
81%
N
O
H2N
O
N
H O
NHBn
O NHTrt
2-31
2-32
2-27
2-30  
 
Scheme 2-9. Protecting group manipulations and construction of tripeptide 2-30. 
2.4 SYNTHESIS OF THE PHOSPHOTYROSINE DERIVATIVES 
Synthesis of the IZD tyrosine derivative began with the synthesis of isothiazolone 2-14 
(Scheme 2-10).  Treatment of 3,3'-disulfanediyldipropanoic acid (2-33) with IBCF and tert-butyl 
amine gave diamide 2-34 in 73% yield.  Then, following the procedure of Combs et al.,22 the 
disulfide was treated with sulfuryl chloride at room temperature to give isothiazole 2-35 which 
was oxidized over three days with mCPBA to give isothiazolone 2-14.  
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Scheme 2-10. Synthesis of IZD coupling partner 2-14. 
 
Mono-iodination of L-phenylalanine followed by methyl ester formation and Cbz addition 
gave iodophenylalanine derivative 2-36 in 64% yield over three steps (Scheme 2-11).  Palladium 
catalyzed addition of pinacol borane afforded boronic ester 2-37, which was further elaborated 
into IZD phospho-mimetic derivative 2-38 by Suzuki coupling with the isothiazolone 2-14. 
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Scheme 2-11. Conversion of phenylalanine (2-16) into IZD phosphotyrosine mimetic 2-38. 
 
Formation of the TDA derivative began with a three-step process of protection of L-
tyrosine (2-16) as the methyl ester, Cbz addition and triflation of the phenol to provide triflate 2-
39 in 85% over three steps (Scheme 2-12).  Stille coupling122 with tributyl(vinyl)tin afforded 
olefin 2-40 in 82% yield.  Subsequent Johnson-Lemieux oxidative cleavage123 afforded aldehyde 
2-41 in 85% yield. 
 28 
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2. Cbz-Cl, Na2CO3, CH2Cl2
3. PhN(Tf)2, Et3N, CH2Cl2
85% (3 steps)
CbzHN
O
OMe
TfO
CbzHN
O
OMePd(PPh3)2Cl2LiCl
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THF/H2O
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2-16
2-39
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Scheme 2-12. Elaboration of tyrosine into aldehyde 2-41. 
 
Using the previously optimized conditions for the condensation to the TDA group, 
treatment of aldehyde 2-41 and dimer 1-16 with 10 equivalents of TFA in CH2Cl2 gave only a 
15% yield of TDA derivative 2-42 along with the starting material even after 18 h (Table 2-2, 
entry 1).  Raising the amount of dimer 1-16 to three equivalents and changing the solvent to a 1:3 
mixture of TFA in CH2Cl2 gave a 74% yield after 13 h, but the reaction was very difficult to 
monitor due to the insoluble nature of dimer 1-16 in the reaction mixture (Table 2-2, entry 2).  
Lowering the ratio to a single equivalent of dimer 1-16 afforded TDA derivative 2-42 in 83% 
yield and, as the reaction advanced, the mixture became homogeneous, making it much easier to 
monitor (Table 2-2, entry 3).  Further lowering of the amount of dimer 1-16 to only a half 
equivalent led to a significant drop in yield to 62% (Table 2-2, entry 4).  The reaction was fully 
optimized with 0.75 equivalents of dimer 1-16 and resulted in the optimal combination of ease of 
performing the reaction with a good product yield of 83% (Table 2-2, entry 5). These conditions 
were also amenable to scale up (Table 2-2, entry 6). 
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Table 2-2. Optimization of TDA phosphotyrosine derivative 2-42. 
 
CbzHN
H
NS
HN CO2Et
O
O
HN
N
H
S
NH
NHS
CO2EtEtO2C
O O
O O
OMe
O
CbzHN
O
H
OMe
O
equiv. 1-16 time
1
3
1
0.5
0.75
0.75
yielda
18 h
13 h
5.5 h
5.5 h
5.5 h
5 h
15%
74%
83%
62%
83%
90%
incomplete rxn
very difficult to monitor
heterogeneous rxn mixture
homogeneous rxn mixture
50 mg
250 mg
notesbentry
1
2
3
4
5
6
10 equiv. TFA
1:3
1:2
1:2
1:2
1.2
TFA/CH2Cl2
1-16
2-422-41
conditions
 
a isolated yield. b 40 – 50 mg scale with a concentration of 0.1 M of 2-41 unless otherwise 
noted. 
2.5 FINAL COUPLING AND COMPLETION OF THE SYNTHESIS 
After saponification of methyl ester 2-38 with lithium hydroxide at 0 °C, the free acid 
was coupled with amine 2-30 using T3P to acquire tetrapeptide 2-43 in 68% over two steps 
(Scheme 2-13).  Decomposition of methyl ester 2-38 was observed if excess lithium hydroxide 
was used or if the temperature was raised to room temperature.  Global deprotection removed the 
trityl, tert-butyl, and, unfortunately, the Cbz group (assignment based on proton NMR and mass 
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spectrometry).  Attempts at reinstalling the Cbz group were unsuccessful due to the limited 
solubility of the intermediate and the difficulty in analyzing the complex reaction mixture. 
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Scheme 2-13. Unsuccessful attempt at construction of final target 2-1. 
 
Returning to IZD phosphotyrosine mimic 2-38, treatment with TFA in the microwave 
cleaved both the tert-butyl and Cbz groups, and subsequent reprotection with Cbz-OSu and 
saponification afforded the phosphotyrosine mimic 2-45 (Scheme 2-14).  The methyl ester was 
more robust toward the saponification conditions after removal of the tert-butyl group and 
transformed smoothly to the carboxylic acid.  Coupling with tripeptide 2-30 afforded the 
protected tetrapeptide and treatment with TFA afforded the target tetrapeptide 2-1. Analysis of 
the crude reaction mixture by LCMS showed a peak at Rt = 5 min. with the desired m/z with a 
shoulder containing the m/z [M + 45] as the base peak.  An additional UV peak was found at Rt = 
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8 min. but no mass ion was obtained.  The peak at Rt = 8 min. was removed from the mixture by 
recrystallization from methanol, leaving the compound with its shoulder in the filtrate.  Further 
purification of this compound by recrystallization in methanol/CH2Cl2, methanol/ethyl acetate, 
methanol/water, and methanol/isopropanol was unsuccessful.  The IZD-tetrapeptide 2-1 was 
isolated as the major component of a mixture in < 90% purity as determined by 1H NMR.  The 
nature of the impurities could not be determined. 
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Scheme 2-14. Synthesis of peptidomimetic 2-1. 
 
TDA-tyrosine methyl ester 2-38 was saponified with lithium hydroxide at 0 °C and 
coupled with amine 2-30 to give compound 2-46 (Scheme 2-15).  Removal of the trityl group 
with TFA afforded the TDA phosphate group mimic containing 2-2.  As with IZD-tetrapeptide 
2-1, TDA analog 2-2 also posed difficulties involved with purification.  The crude material was 
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subjected to HPLC purification and what appeared to be a single peak by LCMS was isolated. 
This peak contained both the desired m/z 911 [M + Na], and another unknown mass of m/z 943. 
By comparing the LC/MS spectra with mass ranges limited to m/z = 910.0 – 912.0 and m/z 942.0 
– 944.0, it was discovered that the two masses corresponded to two separate compounds.  Further 
purification of this compound by recrystallization of methanol/CH2Cl2, methanol/ethyl acetate, 
methanol/water, and methanol/isopropanol was unsuccessful.  The TDA-tetrapeptide 2-2 was 
isolated in 8% yield as the major component of a mixture in < 90% purity as determined by 1H 
NMR. 
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Scheme 2-15. Synthesis of peptidomimetic 2-2. 
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2.6 CONCLUSIONS AND FUTURE DIRECTIONS 
During the first synthetic attempts, a small amount of both tetrapeptides 2-1 and 2-2 were 
isolated in > 90% purity but needed to be submitted for biological testing before full 
characterization could be accomplished.  Subsequent attempts at re-synthesizing the compounds 
were when the purity problems arose.  Both compounds were found to be inactive in a cellular 
based assay as peptidic compounds are known to experience trouble traversing the cell 
membrane.  The compounds were also submitted for binding assay studies, and the results are 
pending. 
Future work on this project, pending any activity shown by these samples, should consist 
of testing both the (S)- and (R)- derivatives of the hydrogenated IZD phosphotyrosine.  Other 
modifications could include lowering the peptide character of the compounds, including 
replacement of the amide with hydrogen bond accepting heterocycles such as a triazole.  Other 
β-turn mimics besides the Freidinger lactam could also be tested. 
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3.0  EXPERIMENTAL SECTION 
All reactions were performed under an N2 atmosphere, and all glassware was flame-dried 
prior to use. Reactions carried out at -78 °C employed a dry ice/acetone bath.  THF was distilled 
over sodium / benzophenone ketyl. Triethylamine and acetonitrile were distilled from CaH2, and 
CH2Cl2 and toluene were purified using an alumina filtration system.  Reactions were monitored 
by TLC analysis (EM Science pre-coated silica gel 60 F254 plates, 250 µm layer thickness) and 
visualization was accomplished with a 254 nm UV light and by staining with a PMA solution (5 
g of phosphomolybdic acid in 100 mL of 95% EtOH), p-anisaldehyde solution (2.5 mL of p-
anisaldehyde, 2 mL of AcOH, and 3.5 mL of conc. H2SO4 in 100 mL of 95% EtOH), Vaughn’s 
reagent (4.8 g of (NH4)6Mo7O24⋅4H2O and 0.2 g of Ce(SO4)2 in 100 mL of a 3.5 M H2SO= 
solution) or a KMnO4 solution (1.5 g of KMnO4 and 1.5 g of K2CO3 in 100 mL of a 0.1 % NaOH 
solution).  Flash chromatography on SiO2 was used to purify the crude mixtures. Microwave 
reactions were performed in a Biotage Initiator microwave reactor.  Melting points were 
determined on a Nicolet Avatar 360 FT-IR spectrometer. 1H and 13C NMR were obtained on a 
Bruker Avance 300 instrument.  Chemical shifts were reported in parts per million with the 
residual solvent peak used as an internal standard. 1H NMR spectra were aquired are tabulated as 
follows: chemical shift, multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, dd = doublet 
of doublet, dt = doublet of triplet, quint = quintet, m = multiplet, br = broad, app = apparent), 
number of protons, and coupling constant(s).  13C NMR spectra were obtained using a proton-
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decoupled pulse sequence with a d1 of 3 sec, and are tabulated by observed peak. LC/MS 
analyses were obtained from a Helwett Packard Series 1100 MSD.  Mass spectra were obtained 
on a Micromass Autospec double focusing instrument. Infrared spectra were measured on a 
Nicolet AVATAR 360 FT-IR E.S.P. spectrometer (KBr or neat) or Smiths Detection IdentifyIR 
FT-IR spectrometer (ATR). 
 
HN
HN S NH
NHS
CO2Et
EtO2C
O O
O O  
3,7-Dicarbethoxyperhydro-1,2,4,5,6,8-dithiatetrazocine-1,1,5,5-tetraoxide-(1-
16).124,125 A solution of sulfonamide (1.00 g, 10.3 mmol) in CH2Cl2/TFA (5:1, 24 mL) was 
treated with ethyl 3,3-diethoxypropanoate (1.86 mL, 10.3 mmol, 1 equiv) and stirred for 3 h. The 
mixture was then filtered through a medium glass frit and washed with MeOH to give dimer 1-16 
as a white solid (1.67 g, 4.30 mmol, 83%): 1H NMR (DMSO-d6, 400 MHz) δ 7.54 (d, 4 H, J = 
9.2 Hz), 5.180 (tt, 2 H, J = 7.2, 9.2 Hz), 4.06 (q, 4 H, J = 7.2 Hz), 2.64 (d, 4 H, J = 7.2 Hz), 1.18 
(t, 6 H, J = 7.2 Hz); 13C NMR (DMSO-d6, 100 MHz) δ 168.6, 62.1, 60.2, 41.1, 14.1. 
 
H2N
NHBn
O
NHTrtO
 
 (S)-2-Amino-N1-benzyl-N5-tritylpentanediamide (2-24).117  A solution of Fmoc-
Gln(Trt)-OH (5.00 g, 8.10 mmol), HBTU (3.73 g, 9.73 mmol, 1.2 equiv) and DIPEA (1.5 mL, 
8.9 mmol, 1.1 equiv) in MeCN (80 mL) was stirred for 20 min. at room temperature. The 
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mixture was then treated with benzylamine (0.89 mL, 8.1 mmol, 1 equiv) and stirred overnight.  
The slurry was then cooled to -10 °C and filtered to give the crude benzyl amide as a white solid 
(5.16 g, 7.38 mmol, 91%).  A slurry of the crude material (1.00 g, 1.43 mmol) in MeCN (20 mL) 
was treated then with diethylamine (1.5 mL, 14 mmol, 10 equiv) and stirred for 4 h at room 
temperature. The mixture became clear during the course of the reaction. The solution was 
condensed, and the resulting residue was purified by chromatography on SiO2 (0 → 12% 
methanol in CH2Cl2) to give glutamine derivative 2-24 as a white solid (698 mg, 1.46 mmol, 
91% over two steps): mp 188.8 – 191.5 °C; [α]D23 + 2.3 (c 1.0, CH2Cl2); FT-IR (ATR) 1644, 
1526, 692; 1H NMR (CDCl3, 400 MHz) δ 7.49 (br t, 1 H, J = 5.2 Hz), 7.27 – 7.15 (m, 20 H), 
6.94 (s, 1 H), 4.34 (d, 2 H, J = 5.6 Hz), 3.23 (app t, 1 H, J = 6.6 Hz), 2.37 (app t, 2 H, J = 6.8 
Hz), 1.95, 1.85 (app t of AB, 2 H, J = 13.8, 6.8 Hz), 1.41 (br s, 2 H); 13C NMR (CDCl3, 100 
MHz) δ 174.7, 171.7, 144.6, 138.4, 128.6, 127.9, 127.6, 127.4, 126.9, 70.4, 54.1, 43.0, 33.9, 
31.1; HRMS (ESI) m/z calcd for C31H32N3O2 [M + H] 478.2495, found 478.2472. 
 
N
BocHN
O
OMe
O
 
(S)-Methyl 2-(3-(tert-butoxycarbonylamino)-2-oxoazepan-1-yl)acetate (2-27).126 A 
solution of of L-(-)-α-amino-caprolactam hydrochloride (1.18 g, 6.95 mmol) and Boc anhydride 
(1.83 g, 8.34 mmol, 1.2 equiv) in THF/H2O (3:1, 60 mL) was treated with triethylamine (2.96 
mL, 20.9 mmol, 3 equiv) and stirred overnight at room temperature. The reaction mixture was 
condensed, diluted with water, and extracted with CH2Cl2 (3 x 50 mL). The combined organic 
layers were washed with brine, dried (MgSO4), filtered, and condensed.  A solution of the crude 
material (assuming 100%) in MeCN (100 mL) at 0 °C was treated with methyl bromoacetate 
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(1.32 mL, 13.8 mmol, 2 equiv) and NaH (95% in mineral oil, 350 mg, 13.8 mmol, 2 equiv), 
warmed to room temperature and stirred overnight. The solution was quenched with saturated 
aqueous NH4Cl (100 mL), the excess MeCN was evaporated, and the resulting aqueous layer 
was extracted with EtOAc (3 x 100 mL). The combined organic layers were dried (MgSO4), 
filtered, and condensed. The resulting residue was purified by chromatography on SiO2 (50 → 
60% EtOAc in hexanes) to give lactam 2-27 as a light yellow solid (2.04 g, 6.79 mmol, 98% over 
2 steps): mp 88.5 – 91.7 °C; [α]D23 + 20.3 (c 1.0, CH2Cl2); FT-IR (ATR) 1748, 1707, 1648; 1H 
NMR (CDCl3, 400 MHz) δ 5.92 (d, 1 H, J = 5.6 Hz), 4.43 (dd, 1 H, J = 10.8, 6.0 Hz), 4.19, 4.16 
(AB, 2 H, J = 17.2 Hz), 3.74 (s, 3 H), 3.68 (dd, 1 H, J = 15.2, 11.6 Hz), 3.19 (dd, 1 H, J = 15.2, 
5.2 Hz), 2.08 – 1.97 (m, 2 H), 1.82 – 1.54 (m, 4 H), 1.44 (s, 9 H); 13C NMR (CDCl3, 100 MHz) δ 
173.7, 169.6, 155.1, 79.4, 53.4, 52.2, 50.7, 50.6, 32.4, 28.4, 27.9, 27.0; HRMS (ESI) m/z calcd 
for C14H24N2O5Na [M + Na] 323.1583, found 323.1584. 
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tert-Butyl (S)-1-(2-((S)-1-(benzylamino)-1,5-dioxo-5-(tritylamino)pentan-2-ylamino)-
2-oxoethyl)-2-oxoazepan-3-ylcarbamate (2-29).  A solution of methyl ester 2-27 (91.0 mg, 
0.302 mmol) in 1,4-dioxane (1.5 mL) was cooled to 0 °C and was treated dropwise with LiOH (2 
M in H2O, 1.06 mL, 2.12 mmol, 7 equiv), warmed to room temperature, and stirred for 40 min. 
The solution was partitioned between CH2Cl2 (5 mL) and water (5 mL). The aqueous layer was 
acidified to pH < 3, the layers were separated, and the aqueous layer was extracted with CH2Cl2 
(3 x 5 mL). The organic layer was dried (MgSO4), filtered, and condensed to give the crude acid 
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as a white foam which was used in the next step without any further purification.  A solution of 
the crude acid (25.3 mg, 0.0884 mmol), amine 2-24 (69.4 mg, 0.107 mmol, 1.2 equiv), HOBt 
(130.9 mg, 0.095 mmol, 1.1 equiv), and EDCI (201.2 mg, 0.1048 mmol, 1.2 equiv) in CH2Cl2 
(0.9 mL) was treated with DIPEA (0.03 mL, 0.2 mmol, 2 equiv) and stirred at room temperature 
for 20 h.  The solution was then diluted with EtOAc (10 mL) and washed with saturated aqueous 
NH4Cl (10 mL), NaHCO3 (10 mL), water (10 mL), and brine (10 mL).  The organic layer was 
dried (MgSO4) filtered and condensed.  The residue was purified by MPLC on SiO2 (0 → 10% 
MeOH in CH2Cl2) to afford Boc protected tripeptide 2-29 as a white solid (53.9 mg, 0.0723 
mmol, 82%, 2 steps): mp 112.0 – 118.9 °C; [α]D23 + 2.4 (c 1.0, CH2Cl2); FT-IR (ATR) 1642, 
1508, 1489, 728, 697; 1H NMR (CDCl3 + TMS, 400 MHz) δ 7.32 (d, 1 H, J = 6.8 Hz), 7.26 – 
7.18 (m, 20 H), 7.10 (s, 1 H), 7.06 (br t, 1 H, J = 5.2 Hz), 5.80 (d, 1 H, J = 5.6 Hz), 4.35 (dd, 1 H, 
J = 13.2, 5.2 Hz), 4.26 (dd, 1 H, J = 14.8, 5.2 Hz), 3.91, 3.77 (AB, 2 H, J = 15.6 Hz), 3.59 (dd, 1 
H, J = 14.8, 12.0 Hz), 3.13 (dd, 1 H, J = 14.8, 3.6 Hz), 2.51 (app tt, 1 H, J = 15.6, 4.4 Hz), 2.35 
(app dt, 1 H, J = 15.6, 6.0 Hz), 2.07-1.88 (m, 4 H), 1.75-1.62 (m, 2 H), 1.52-1.35 (m, 10 H); 13C 
NMR (CDCl3, 100 MHz) δ 174.0, 172.2, 170.7, 168.6, 154.9, 144.4, 138.0, 128.6, 128.5, 127.9, 
127.6, 127.3, 126.9, 79.3, 70.6, 53.6, 53.3, 52.6, 51.1, 43.4, 33.4, 32.2, 28.7, 28.4, 27.8, 26.8; 
HRMS (ESI) m/z calcd for C44H51N5O6Na [M + Na] 768.3739, found 768.3737. 
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(9H-Fluoren-9-yl)methyl-(S)-1-(2-((S)-1-(benzylamino)-1,5-dioxo-5-(tritylamino) 
pentan-2-ylamino)-2-oxoethyl)-2-oxoazepan-3-ylcarbamate (2-32).117  A solution of lactam 2-
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27  (915 mg, 3.05 mmol) in THF/water (4:1, 20 mL) was treated with 2 N aqueous LiOH (7.6 
mL, 15 mmol, 5 equiv) and stirred at room temperature for 2 h. The solvent was reduced under 
vacuum, diluted with sat. NaHCO3 (10 mL) and was washed with EtOAc (3 x 30 mL). The 
aqueous layer was then acidified to pH < 3 and extracted with EtOAc (3 x 40 mL). The 
combined organic layers were dried (MgSO4), filtered and condensed.  A solution of the crude 
material (assuming 100%) was stirred in 4 M HCl in dioxane (15 mL) overnight at room 
temperature. The solvent was removed under vacuum.  A solution of the crude material 
(assuming 100%) in 0.25 M aqueous Na2CO3 (36.5 mL, 9.13 mmol, 3 equiv) was treated with 
Fmoc-OSu (1.18 mg, 3.35 mmol, 1.1 equiv) in dioxane (15 mL) and stirred overnight. The 
resulting solution was diluted with sat. NaHCO3 (10 mL) and washed with EtOAc (3 x 30 mL). 
The aqueous layer was acidified to pH < 3 and extracted with EtOAc (3 x 50 mL). The combined 
organic layers were then dried (MgSO4), filtered and condensed to give a white solid that was 
used without further purification. 
A solution of crude carboxylic acid 2-31 (475 mg, 1.16 mmol), glutamine derivative 2-24 
(666 mg, 1.39 mmol, 1.2 equiv), and DIPEA (0.38 mL, 2.3 mmol, 2 equiv) in CH2Cl2 (5.8 mL) 
at 0 °C was treated with T3P (50 wt% in EtOAc, 0.81 mL, 1.35 mmol, 1.2 equiv), allowed to 
warm to room temperature, and stirred for 2 h. The solution was then diluted with EtOAc (25 
mL) and washed with NH4Cl (25 mL), NaHCO3 (25 mL), and brine (25 mL). The organic layer 
was dried (MgSO4), filtered and condensed. The resulting residue was purified by 
chromatography on SiO2 (EtOAc) to give Fmoc protected tripeptide 2-32 as a white solid (777 
mg, 0.895 mmol, 77%): mp 138.5 – 143.9 °C; [α]D23 + 1.4 (c 1.0, CH2Cl2); FT-IR (ATR) 1644, 
1487, 1444, 740, 697; 1H NMR (CDCl3 + TMS, 400 MHz) δ 7.75 (d, 2 H, J = 10.8 Hz), 7.60 (d, 
2 H, J = 7.2 Hz), 7.38 (br t, 3 H, J = 6.4 Hz), 7.31 – 7.18 (m, 23 H), 7.06 – 7.02 (m, 2 H), 6.08 
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(d, 1 H, J = 5.6 Hz), 4.43 – 4.19 (m, 7 H), 3.97, 3.80 (AB, 2 H, J = 16.0 Hz), 3.58 (dd, 1 H, J = 
14.8, 12.8 Hz), 3.13 (dd, 1 H, J = 15.2, 2.8 Hz), 2.55 – 2.52 (m, 1 H), 2.40 – 2.36 (m, 1 H), 2.10 
– 1.68 (m, 6 H), 1.60 – 1.40 (m, 2 H); 13C NMR (CDCl3, 100 MHz) δ 173.8, 172.3, 170.7, 168.5, 
155.3, 144.4, 144.0, 143.9, 141.3, 138.0, 128.6, 128.6, 128.0, 127.6, 127.3, 127.0, 127.0, 125.1, 
119.9, 70.7, 66.8, 53.8, 53.5, 52.6, 51.0, 47.2, 43.4, 33.5, 32.0, 28.8, 27.7, 26.8; HRMS (ESI) m/z 
calcd for C54H53N5O6Na [M + Na] 890.3894, found 890.3840. 
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(S)-2-(2-((S)-3-Amino-2-oxoazepan-1-yl)acetamido)-N1-benzyl-N5-tritylpentane 
diamide (2-30).117  A solution of Fmoc protected tripeptide 2-32 (554 mg, 0.638 mmol) in 20% 
diethylamine in MeCN (8.0 mL) stirred at room temperature for 7 h. During the course of the 
reaction, a white solid precipitated. The mixture was diluted with CH2Cl2 until it became a clear 
solution and then concentrated under vacuum. The resulting residue was purified by MPLC 
(silica, 0 → 20 % MeOH in CH2Cl2) to give amine 2-30 as a white solid (335 mg, 519 mmol, 81 
%): mp 100.0 – 110.0 °C; [α]D23 + 0.2 (c 1.0, CH2Cl2); FT-IR (ATR) 1644, 1515, 1489, 697; 1H 
NMR (500 Hz, CDCl3 + TMS) δ 7.64 (d, 1 H, J = 7.0 Hz), 7.29 – 7.18 (m, 20 H), 7.10 (br t, 1 H, 
J = 5.5 Hz), 6.96 (s, 1 H), 4.42 – 4.30 (m, 3 H), 4.19, 3.58 (AB, 2 H, J = 16.0 Hz), 3.46 – 3.41 
(m, 2 H), 3.06 (dd, 1 H, J = 10.5, 4.5 Hz), 2.62 (dt, 1 H, J = 16.5, 6.5 Hz), 2.44 (dt, 1 H, J = 16.5, 
5.5 Hz), 2.05 (dd, 2 H, J = 12.5, 6.5 Hz), 1.87 – 1.84 (m, 1 H), 1.74 (d, 1 H, J = 14.0 Hz), 1.68 – 
1.55 (m, 4 H), 1.44 – 1.36 (m, 2 H); 13C NMR (CDCl3, 100) δ 177.7, 172.5, 170.9, 169.3, 144.3, 
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138.2, 128.6, 128.5, 127.9, 127.5, 127.2, 127.0, 70.6, 53.6, 53.5, 52.7, 50.2, 43.2, 33.5, 33.4, 
28.0, 27.7, 26.9; HRMS (ESI) m/z calcd for C39H43N5O4Na [M + Na] 668.3213, found 668.3216. 
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3,3'-Disulfanediylbis(N-tert-butylpropanamide) (2-34).127  A suspension of 3,3'-
dithiodipropionic acid (2.00 g, 9.42 mmol) and NMM (2.50 mL, 22.6 mmol, 2.4 equiv) in 
CH2Cl2 (40 mL) was cooled to -20 °C, treated with IBCF (2.95 mL, 22.6 mmol, 2.4 equiv), and 
stirred at -20 °C for 30 min. The solution was then treated with tert-butyl amine (5.10 mL, 47.1 
mmol, 5 equiv), warmed to room temperature, and stirred for 2 h. The solution was then 
quenched with saturated NaHCO3 (150 mL), diluted with EtOAc (150 mL) and separated. The 
organic layer was washed with saturated NH4Cl (150 mL), saturated NaHCO3 (150 mL), and 
brine (150 mL). The organic layer was dried (MgSO4), filtered and concentrated. The resulting 
residue was purified by chromatography on SiO2 (33 → 50% EtOAc in hexanes) to give 
disulfide 2-34 as white crystals (2.19 g, 6.83 mmol, 73%): mp 122.8 – 124.0 °C; FT-IR (ATR) 
3267, 3077, 3963, 2963, 1636, 1556, 1223; 1H NMR (CDCl3, 400 MHz) δ 5.89 (br s, 2 H), 2.91 
(t, 4 H, J = 5.4 Hz), 2.47 (t, 4 H, J = 5.4 Hz), 1.32 (s, 18 H); 13C NMR (CDCl3, 100 MHz) δ 
170.1, 51.2, 36.3, 34.1, 28.7; HRMS (ESI) m/z calcd for C14H28N2O2S2Na [M + Na] 343.1490, 
found 343.1472. 
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2-tert-Butyl-5-chloro-1,1-dioxo-1,2-dihydro-1λ6-isothiazol-3-one (2-14).  Prepared 
from disulfide 2-34 according to a literature procedure:22  1H NMR (CDCl3, 400 MHz) δ 6.56 (s, 
1 H), 1.69 (s, 9 H); 13C NMR (CDCl3, 100 MHz) δ 158.1, 143.7, 123.7, 62.4, 27.7. 
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(S)-Methyl 2-(benzyloxycarbonylamino)-3-(4-iodophenyl)propanoate (2-36).128  A 
flask was charged with L-phenylalanine (2-16) (10.0 g, 59.6 mmol), sodium iodate (2.4 g, 12 
mmol, 0.2 equiv), iodine (6.1 g, 23.9 mmol, 0.4 equiv), AcOH (53 mL), and H2SO4 (7 mL) and 
warmed to 70 °C for 1.5 d. The solution was treated with NaIO4 (3 x 650 mg, 2.98 mmol, 0.05 
equiv) until the solution changed from dark purple to orange. The solution was then cooled to 
room temperature and the volatile components were removed under vacuum. The resulting 
orange oil was diluted to 200 mL with water. The solution was washed with Et2O (200 mL) and 
CH2Cl2 (200 mL). The aqueous layers were acidified to pH = 5 to give a white sticky precipitate. 
The solid was immersed in water (1 L) and basified with 10 M NaOH until it was dissolved. The 
solution was acidified to pH = 5 and the product precipitated out slowly over 2 d.  A suspension 
of the crude iodide (assuming 100%) in MeOH (180 mL, 0.3 M) at 0 °C was treated with SOCl2 
(44 mL, 596 mmol, 10 equiv) dropwise over 30 min. The solution was allowed to warm to room 
temperature and stirred overnight. The solution was condensed into a light yellow solid.  A 
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suspension of the crude methyl ester (assuming 100%) and Cbz-Cl (9.60 mL, 65.6 mmol, 1.1 
equiv) in CH2Cl2 (300 mL) was stirred vigorously at 0 °C. The mixture was treated with aqueous 
Na2CO3 (2 M, 33 mL, 65.6 mmol, 1.1 equiv) and stirred at room temperature overnight. The 
mixture was diluted with CH2Cl2 (100 mL) and water (300 mL), the layers were separated and 
the aqueous layer was extracted with CH2Cl2 (2 x 400 mL). The combined organic layers were 
washed with brine, dried (MgSO4), and purified by chromatography on SiO2 (30 → 60% EtOAc 
in hexanes) to give iodide 2-36 as a white solid (16.76 g, 38.16 mmol, 64% over 3 steps):  mp 
93.9 – 104.0 °C; [α]D23 – 17.7 (c 1.0, MeOH); FT-IR (ATR) 1743, 1727, 1689, 1539, 1245; 1H 
NMR (CDCl3) δ 7.59 (dt, 2 H, J = 8.0 Hz, 2.0 Hz), 7.40 – 7.32 (m, 5 H), 6.84 (d, 2 H, J = 8.0 
Hz), 5.25 (d, 1 H, J = 8.0 Hz), 5.13, 5.08 (AB, 2 H, J = 12.0 Hz), 4.65 (dd, 1 H, J = 14.0, 6.0 
Hz), 3.73 (s, 3 H), 3.11 (dd, 1 H, J = 14.0, 5.6 Hz), 3.01 (dd, 1 H, J = 14.0, 6.0 Hz); 13C NMR 
(CDCl3) δ 171.6, 155.5, 137.6, 136.1, 135.4, 131.2, 128.5, 128.2, 128.1, 92.6, 67.0, 54.5, 52.4, 
37.8; HRMS (ESI) m/z calcd for C18H18INO4Na [M + Na] 462.0178, found 462.0132. 
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(S)-Methyl-2-(benzyloxycarbonylamino)-3-(4-(4,4,5,5-tetramethyl-1,3,2-
dioxaborolan-2-yl)phenyl)propanoate (2-37).  A solution of iodide 2-36 (559 mg, 1.27 mmol), 
bis(pinacolato)diboron (359 mg, 1.40 mmol, 1.1 equiv), KOAc (378 mg, 3.81 mmol, 3 equiv) 
and Pd(dppf)Cl2 (279 mg, 0.381 mmol, 30 mol%) in DMSO was heated to 80 °C for 2.5 h. The 
cooled reaction mixture was diluted with water (25 mL) and extracted with EtOAc (4 x 25 mL). 
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The combined organic layers were washed with brine (3 x 100 mL), dried (MgSO4), filtered, and 
concentrated. The resulting residue was purified using chromatography on SiO2 (30 → 60% 
EtOAc in hexanes) to give boronic ester 2-37 as a yellow oil (471 mg, 1.07 mmol, 84%): [α]D23 
+ 34.7 (c 1.0, CH2Cl2); FT-IR (ATR) 2977, 1720, 1357, 1142; 1H NMR (CDCl3, 400 MHz) δ 
7.74 (d, 2 H, J = 8.0 Hz), 7.36 – 7.32 (m, 5 H), 7.12 (d, 2 H, J = 8.0 Hz), 5.24 (d, 1 H, J = 8.0 
Hz), 5.12, 5.08 (AB, 2 H, J = 12.4 Hz), 4.68 (dd, 1 H, J = 14.0, 6.0 Hz), 3.72 (s, 3 H), 3.16, 3.10 
(ABX, 2 H, J = 8.0, 6.0 Hz), 1.35 (s, 12 H); 13C NMR (CDCl3, 100 MHz) δ 171.8, 155.5, 138.8, 
136.2, 135.0, 132.0, 128.6, 128.5, 128.1, 128.0, 83.7, 66.9, 54.7, 52.3, 38.4, 24.9, 24.8; HRMS 
(ESI) m/z calcd for C24H30BNO6Na [M + Na] 462.2064, found 462.2069. 
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(S)-Methyl-2-(benzyloxycarbonylamino)-3-(4-(2-tert-butyl-1,1-dioxido-3-oxo-2,3-
dihydroisothiazol-5-yl)phenyl)propanoate (2-38).  A solution of boronic ester 2-37 (1.858 g, 
4.229 mmol), isothiazolone 2-14 (1.04 g, 4.65 mmol, 1.1 equiv), K2CO3 (2.95 g, 21.1 mmol, 5 
equiv), and Pd(dppf)Cl2 (464 mg, 0.634 mmol, 15 mol%) in dioxane/water (10:1, 28 mL) was 
flushed with Ar for 15 min. and then heated to 100 °C for 3.5 h. The mixture was cooled to room 
temperature, diluted with EtOAc, and filtered through a cotton plug. The organic layer was 
washed with water, dried (MgSO4), filtered and condensed. The resulting residue was purified by 
chromatography on SiO2 (10 → 60% EtOAc in hexanes) to give IZD phosphotyrosine derivative 
2-38 as a yellow solid (1.27 g, 2.54 mmol, 60%): mp 51.9 °C (dec.); [α]D23 + 45.2 (c 1.0, 
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CH2Cl2); FT-IR (ATR) 1707, 1510, 1327, 1269, 1152; 1H NMR (CDCl3, 400 MHz) δ 7.76 (d, 2 
H, J = 8.0 Hz), 7.37 – 7.33 (m, 5 H), 7.24 (d, 2 H, J = 8.0 Hz), 6.61 (s, 1 H), 5.33 (d, 1 H, J = 8.0 
Hz), 5.12, 5.08 (AB, 2 H, J = 12.4 Hz), 4.70 (dd, 1 H, J = 13.6, 6.0 Hz), 3.74 (s, 3 H), 3.24 (dd, 1 
H, J = 14.0, 5.6 Hz), 3.12 (dd, 1 H, J = 14.0, 5.6 Hz), 1.74 (s, 9 H); 13C NMR (CDCl3, 100 MHz) 
δ 171.4, 160.4, 155.5, 150.2, 141.0, 136.0, 130.4, 128.5, 128.3, 128.1, 128.0, 123.1, 119.1, 67.1, 
61.4, 54.5, 52.5, 38.1, 27.7; HRMS (ESI) m/z calcd for C25H28N2O7SNa [M + Na] 523.1515, 
found 523.1542. 
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(S)-Methyl-2-(benzyloxycarbonylamino)-3-(4-(trifluoromethylsulfonyloxy)phenyl) 
propanoate (2-39).  A suspension of L-tyrosine (2-16) (2.00 g, 10.9 mmol) in MeOH (60 mL) at 
0 °C was treated dropwise with SOCl2 (8.0 mL, 109 mmol, 10 equiv) over 5 min and was then 
heated to reflux for 4 h.   The cooled solution was condensed to approx. 1/3 volume and was 
diluted with Et2O (250 mL).  The white precipitate was filtered off and dried under vacuum 
overnight. A vigorously stirred suspension of the crude material (assuming 100%) in CH2Cl2 (55 
mL) at 0 °C was treated with benzyl chloroformate (1.6 mL, 10.9 mmol, 1 equiv) and sodium 
carbonate (5.5 mL, 2 M in water, 10.9 mmol, 1 equiv).  The mixture was warmed to room 
temperature and stirred for 4 h.  The mixture was then diluted with water (50 mL), separated and 
the aqueous layer was extracted with CH2Cl2 (2 x 50 mL).  The combined organic layers were 
washed with brine, dried (MgSO4), filtered, and concentrated.  A solution of the crude material 
(assuming 100%) and Tf2NPh (4.1 g, 11.5 mmol, 1.05 equiv) in dry CH2Cl2 (55 mL) at 0 °C was 
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treated with triethylamine (1.7 mL, 12.0 mmol, 1.1 equiv) dropwise over 5 min. The solution 
was stirred at 0 °C for 1 h, allowed to warm to room temperature, and stirred for 1 h. The 
solution was then diluted with Et2O (200 mL) and washed with water (50 mL), 1 M NaOH (50 
mL), water (50 mL), and brine (50 mL). The organic layer was dried (MgSO4), filtered, 
condensed and purified by chromatography on SiO2 (20 → 40% EtOAc in hexanes) to give 
triflate 2-39 as a white solid (4.28 g, 9.27 mmol, 85% over 3 steps): mp 71.3 – 73.2 °C; [α]D23 + 
36.2 (c 1.0, CH2Cl2); FT-IR (ATR) 1746, 1690, 1534, 1200, 1135, 882; 1H NMR (CDCl3 + 
TMS, 400 MHz) δ 7.35 – 7.32 (m, 5 H), 7.16 (s, 4 H), 5.39 – 5.31 (m, 1 H), 5.11, 5.06 (AB, 2 H, 
J = 12.0 Hz), 4.65 (dd, 1 H, J = 14.0, 6.4 Hz), 3.70 (s, 3 H), 3.18 (dd, 1 H, J = 14.0, 5.6 Hz), 3.07 
(dd, 1 H, J = 14.0, 6.8 Hz); 13C NMR (CDCl3, 100 MHz) δ 171.5, 155.5, 148.5, 136.6, 136.0, 
131.0, 128.5, 128.2, 128.1, 121.2, 118.6 (q, JCF = 310 Hz), 67.0, 54.6, 52.4, 37.5; HRMS (ESI) 
m/z calcd for C19H18F3NO7SNa [M + Na] 484.0654, found 484.0672. 
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(S)-Methyl-2-(benzyloxycarbonylamino)-3-(4-vinylphenyl)propanoate (2-40).  A 
solution of triflate 2-39 (2.02 g, 4.38 mmol), LiCl (558 mg, 13.1 mmol, 3 equiv), and 
Pd(PPh3)2Cl2 (318 mg, 0.444 mmol, 10 mol%) in degassed DMF (73 mL) was treated with 
tributyl(vinyl)tin (2.00 mL, 6.57 mmol, 1.5 equiv) and heated to 90 °C for 18 h. The cooled 
mixture was diluted with Et2O (200 mL) and washed with saturated aqueous LiCl (3 x 150 mL), 
10% aqueous KF (3 x 150 mL) and brine (150 mL). The organic layer was dried (MgSO4), 
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filtered and condensed. The resulting residue was purified by chromatography on SiO2 (20 → 
40% EtOAc in hexanes) to give olefin 2-40 as a yellow oil (1.11 g, 3.27 mmol, 75%): [α]D23 + 
39.2 (c 1.0, CH2Cl2); FT-IR (ATR) 3029, 2950, 1709, 1510, 1210; 1H NMR (CDCl3, 400 MHz) 
δ 7.39 – 7.32 (m, 7 H), 7.07 (d, 2 H, J = 8.0 Hz), 6.70 (dd, 1 H, J = 17.6 Hz, 10.8 Hz), 5.74 (d, 1 
H, J = 17.6 Hz), 5.29 (d, 1 H, J = 8.0 Hz), 5.25 (d, 1 H, J = 10.8 Hz), 5.13, 5.09 (AB, 2 H, J = 
12.0 Hz), 4.68 (dd, 1 H, J = 14.0, 6.0 Hz), 3.74 (s, 3 H), 3.15 (dd, 1 H, J = 8.4 Hz, 5.6 Hz), 3.09 
(dd, 1 H, J = 8.4 Hz, 6.0 Hz); 13C NMR (CDCl3, 100 MHz) δ 171.9, 155.6, 136.4, 136.3, 136.2, 
135.2, 129.4, 128.4, 128.1, 128.0, 126.4, 113.7, 66.9, 54.7, 52.3, 37.8; HRMS (ESI) m/z calcd for 
C20H21NO4Na [M + Na] 362.1368, found 362.1398. 
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(S)-Methyl 2-(benzyloxycarbonylamino)-3-(4-formylphenyl)propanoate (2-41).128  A 
solution of olefin 2-40 (761 mg, 2.24 mmol) in THF/H2O (3:1, 25 mL) was treated with one drop 
of 0.1 M OsO4 in toluene (0.2 mL, 0.02 mmol, 1 mol%) and stirred until the solution was dark 
brown. The reaction mixture was then treated with NaIO4 (1.45 mg, 6.73 mmol, 3 equiv), stirred 
for 2 h at room temperature, diluted with water (40 mL) and extracted with CH2Cl2 (3 x 40 mL). 
The combined organic layers were washed with brine, dried (MgSO4), filtered and condensed. 
The resulting residue was purified by MPLC on SiO2 (21 → 42% EtOAc in hexanes) to give 
aldehyde 2-41 as a tan solid (674 mg, 1.97 mmol, 88%): mp 67.5 – 69.1 °C; [α]D23 + 53.9 (c 1.0, 
CH2Cl2); FT-IR (ATR) 1739, 1690; 1H NMR (CDCl3 + TMS, 400 MHz) δ 9.97 (s, 1 H), 7.78 (d, 
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2 H, J = 8.0 Hz), 7.37 – 7.31 (m, 5 H), 7.27 (d, 2 H, J = 8.0 Hz), 5.32 (br s, 1 H), 5.12, 5.06 (AB, 
2 H, J = 12.0 Hz), 4.71 (dd, 1 H, J = 13.6, 6.4 Hz), 3.73 (s, 3 H), 3.25 (dd, 1 H, J = 13.6, 5.6 Hz), 
3.13 (dd, 1 H, J = 13.6, 6.4 Hz); 13C NMR (CDCl3, 100 MHz) δ 191.8, 171.5, 155.5, 143.0, 
136.0, 135.3, 130.0, 129.9, 128.5, 128.3, 128.1, 67.0, 54.5, 52.5, 38.4; HRMS (ESI) m/z calcd for 
C19H19NO5Na [M + Na] 364.1161, found 364.1171. 
 
CbzHN
H
NS
HN CO2Et
O
O
O
OMe
 
(S)-Methyl-2-(benzyloxycarbonylamino)-3-(4-(1,1-dioxo-1,2,3,6-tetrahydro-1λ6-
[1,2,6]thiadiazine 4-carboxylic acid ethyl ester-3-yl)phenyl)propanoate (2-42).  A slurry of 
aldehyde 2-41 (250 mg, 0.732 mmol) and dimer 1-16 (213 mg, 0.549 mmol, 0.75 equiv) in 
CH2Cl2 (6.0 mL) was treated dropwise with TFA (3.0 mL) and stirred for 4.4 h. The mixture was 
concentrated and the resulting residue was purified by MPLC on SiO2 (41 → 62% EtOAc in 
hexanes) to give thiadiazine 2-42 as a white solid as a mixture of diastereomers (340 mg, 0.657 
mmol, 90%): mp 70.1 – 84.6 °C; [α]D23 + 30.0 (c 1.0, CH2Cl2); FT-IR (ATR) 1692, 1633, 1156; 
1H NMR (CDCl3, 400 MHz) δ 7.70 (br s, 1 H), 7.44 (br s, 1 H), 7.40 – 7.30 (m, 5 H), 7.25 (d, 2 
H, J = 8.0 Hz), 7.10 – 7.07 (m, 2 H), 5.52 (t, 1 H, J = 7.2 Hz), 5.37 (t, 1 H, J = 8.0 Hz), 5.09, 
5.07 (AB, 2 H), 4.90 (2d, 1 H, J = 8.4 Hz), 4.65 – 4.63 (m, 1 H), 4.06 – 3.95 (m, 2 H), 3.70 (s, 3 
H), 3.14 – 3.04 (m, 2 H), 1.00 (dt, 3 H, J = 6.4, 6.4 Hz); 13C NMR (CDCl3, 100 MHz) δ 172.2, 
172.1, 165.5, 155.8, 138.3, 137.0, 136.1, 136.0, 135.9, 135.8, 129.4, 129.4, 128.5, 128.5, 128.2, 
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128.1, 127.9, 106.1, 106.0, 67.1, 60.5, 59.1, 59.0, 54.8 (2C), 52.5, 37.9, 37.8, 13.9; HRMS (ESI) 
m/z calcd for C24H27N3O8SK [M + K] 556.1156, found 556.1188. 
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CbzHN-(tert-butyl-IZD)Tyr-(2-amido-ε-lactam)-Gly-Glu(Trt)-NHBn (2-43).  A 
solution of IZD phosphotyrosine derivative 2-38 (103.3 mg, 0.2064 mmol) in THF at 0 °C was 
treated with 0.2 N LiOH (2.0 mL, 0.4 mmol, 2 equiv) that had been pre-cooled to 0 °C.  The 
solution was stirred for 10 min then quenched with 0.1 N HCl (4 mL), warmed to room 
temperature and acidified with 1 N HCl (0.5 mL). The mixture was then extracted with EtOAc (3 
x 10 mL). The combined organic layers were washed with brine, dried (MgSO4), filtered and 
condensed.  A solution of the crude material (100 mg, 0.206 mmol), amine 2-30 (159 mg, 248 
mmol, 1.2 equiv), and DIPEA (0.07 mL, 0.4 mmol, 2 equiv) in CH2Cl2 (2 mL) at 0 °C was 
treated with T3P (50 wt% in EtOAc, 0.15 mL, 0.25 mmol, 1.2 equiv), allowed to warm to room 
temperature, and stirred for 2 h.  The solution was diluted with EtOAc (10 mL) and washed with 
saturated aqueous NH4Cl (10 mL), saturated aqueous NaHCO3 (10 mL), and brine (10 mL).  The 
organic layer was then dried (MgSO4), filtered and condensed.  The resulting residue was 
purified by chromatography on SiO2 (EtOAc) to afford tetrapeptide 2-43 as a yellow solid (157 
mg, 0.147 mmol, 68% over 2 steps): mp 140.1 – 147.4 °C; FT-IR (ATR) 1709, 1640, 1487, 697; 
1H NMR (CDCl3 + TMS, 500 MHz) δ 7.61 (d, 2 H, J = 6.0 Hz), 7.32 – 7.17 (m, 25 H), 7.15 – 
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7.09 (m, 1 H), 6.96 (br s, 1 H), 6.58 (s, 1 H), 5.50 – 5.46 (m, 1 H), 5.06, 5.01 (AB, 2 H, J = 9.6 
Hz), 4.53 – 4.51 (m, 2 H), 4.31 – 4.26 (m, 3 H), 3.93 (s, 2 H), 3.57 (t, 1 H, J = 11.7 Hz), 3.17 – 
3.10 (m, 2 H), 3.02 – 3.00 (m, 1 H), 2.57 – 2.47 (m, 1 H), 2.41 – 2.31 (m, 1 H), 2.10 – 1.75 (m, 6 
H), 1.71 (s, 9 H), 1.60 – 1.36 (m, 2 H); 13C NMR (CDCl3 + TMS, 100 MHz) δ 173.3, 172.3, 
170.8, 169.1, 168.4, 160.5, 155.7, 150.4, 144.4, 141.5, 138.0, 130.6, 128.7, 128.6, 128.5, 128.2, 
128.1, 128.1, 128.0, 127.5, 127.4, 127.0, 123.0, 119.1, 70.7, 67.1, 61.4, 55.4, 53.3, 52.6, 52.5, 
52.5, 51.0, 43.4, 38.6, 38.6, 33.6, 31.4, 29.3, 27.8, 27.6, 26.7; HRMS (ESI) m/z calcd for 
C63H67N7O10SNa [M + Na] 1136.4568, found 1136.4562. 
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H2N-(H-IZD)Tyr-(2-amido-ε-lactam)-Gly-Glu-NHBn (2-44). A solution of IZD-
protected tetrapeptide 2-43 (44.9 mg, 0.0403 mmol) in TFA (1.0 mL) was heated in the 
microwave to 130 °C for 1 min.  The reaction mixture was condensed to a brown solid.  The 
solid was dissolved in a minimum amount of methanol and precipitated with CH2Cl2 to give 
fully deprotected tetrapeptide 2-44 as a light red solid (15.8 mg, 0.0199 mmol, 49%, 60% pure 
by LC/MS): 1H NMR (CDCl3 + TMS, 400 MHz) δ 7.84 (d, 2 H, J = 8.4 Hz), 7.44 (d, 2 H, J = 
8.0 Hz), 7.27 – 7.24 (m, 5 H), 7.22 – 7.19 (m, 1 H), 6.80 (s, 1 H), 4.78 (d, 1 H, J = 11.2 Hz), 
4.39, 4.34 (AB, 4 H, J = 14.8 Hz), 4.26 – 4.19 (m, 2 H), 4.05 (d, 1 H, J = 16.4 Hz), 3.77 (dd, 1 H, 
J = 15.6, 12.4 Hz), 3.05 (dd, 1 H, J = 14.0 Hz, 8.8 Hz), 2.33 – 2.28 (m, 2 H), 2.16 – 2.07 (m, 1 
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H), 2.00 – 1.90 (m, 3 H), 1.85 – 1.60 (m, 4 H); LC/MS (30 → 100% MeCN in water with 5% 
MeOH, ESI+) m/z (rel intensity) Rt = 1.29 min.: 704.5 ([M + Na]+, 74), 726.5 ([M + 2Na – H]+, 
100); 
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(S)-Methyl-2-(benzyloxycarbonylamino)-3-(4-(1,1-dioxido-3-oxo-2,3-
dihydroisothiazol-5-yl)phenyl)propanoate (2-45).  A solution of tert-butyl IZD tyrosine 
derivative 2-38 (200.2 mg, 0.4000 mmol) in TFA (2.0 mL) was heated in the microwave for 2 
min at 130 °C. The mixture was condensed and purified by reverse phase MPLC (C18, 5 → 20% 
MeCN in water + 0.1% TFA) to give the free amine as a brown solid (131.1 mg, 0.3089 mmol, 
77%). 
 A solution of the amine (131.1 mg, 0.3058 mmol) in CH2Cl2 (3 mL) was cooled to 0 °C 
and treated with triethylamine (0.17 mL, 1.2 mmol, 4 equiv) and Cbz-OSu (93.3 mg, 0.367 
mmol, 1.2 equiv), warmed to room temperature and stirred for 5.5 h.  The mixture was 
condensed and subjected to MPLC purification on SiO2 (0 → 20% MeOH in CH2Cl2) to give the 
triethylamine salt of 2-45.  The residue was then dissolved in EtOAc (3 mL) and washed with 0.1 
N HCl (3 x 3 mL) and brine.  The organic layer was dried (MgSO4) filtered and condensed to 
give IZD phosphotyrosine derivative 2-45 as a tan solid (93.8 mg, 0.211 mmol, 68%): mp 169.8 
– 172.9 °C; [α]D23 -27.4 (c 1.0, acetone); FT-IR (ATR) 3349, 2947, 2682, 1715, 1685, 1336, 
1157; 1H NMR (acetone-d6, 400 MHz) δ 11.23 (br s, 1 H), 7.77 (d, 2 H, J = 8.4 Hz), 7.52 (d, 2 
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H, J = 8.4 Hz), 7.36 – 7.26 (m, 5 H), 7.16 (s, 1 H), 6.77 (d, 1 H, J = 8.4 Hz), 5.02 (s, 2 H), 4.55 
(dd, 1 H, J = 9.2, 5.2 Hz), 3.30 (dd, 1 H, J = 14.0, 5.2 Hz), 3.11 (dd, 1 H, J = 14.0, 9.6 Hz); 13C 
NMR (acetone-d6, 100 MHz) δ 172.6, 161.7, 156.8, 153.8, 143.7, 138.0, 131.4, 129.2, 129.0, 
128.6, 128.5, 124.2, 120.2, 66.8, 56.0, 52.5, 38.0; HRMS (ESI) m/z calcd for compound 
C21H20N2O7SNa [M + Na] 467.0889, found 467.0865. 
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CbzHN-(H-IZD)Tyr-(2-amido-ε-lactam)-Gly-Glu-NHBn (2-1).  A solution of methyl 
ester 2-45 (49.7 mg, 0.112 mmol) in THF (1.1 mL) was and treated with 0.2 N LiOH (1.7 mL, 
0.34 mmol, 3 equiv) and stirred for 1.5 h. The mixture was acidified to pH < 3 using 0.1 N HCl 
and extracted with EtOAc (3 x 4 mL). The combined organic layers were washed with brine, 
dried (MgSO4), filtered and condensed.  A solution of the crude acid (assuming 100%), amine 2-
30 (86.7 mg, 0.134 mmol, 1.2 equiv), and DIPEA (0.037 mL, 0.22 mmol, 2 equiv) in DMF (1.2 
mL) was cooled to 0 °C and treated with T3P (0.080 mL, 0.134 mmol, 1.2 equiv), warmed to 
room temperature and stirred for 5 h. The solution was then diluted with CH2Cl2 (5 mL) and 
washed with saturated LiCl solution (5 mL), NH4Cl (5 mL), and NaHCO3 (5 mL). During the 
NaHCO3 wash the solution became a thick emulsion and the mixture was re-acidified and 
separated. The organic layer was then washed with brine, condensed and filtered.  A suspension 
of the crude protected tetrapeptide (assuming 100%) and triethylsilane (0.021 mL, 0.13 mmol, 
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1.2 equiv) in CH2Cl2 (0.8 mL) was treated with TFA (0.2 mL) and stirred at room temperature 
for 3 h.  The suspension was condensed under a stream of air.  An unidentified impurity was 
recrystallized from the reaction mixture using MeOH (approx. 2 mL) leaving impure tetrapeptide 
2-1 in the filtrate.  The filtrate was concentrated and attempts at further purification by 
recrystallization using MeOH/H2O, MeOH/CH2Cl2, MeOH/EtOAc, MeOH/Et2O, and MeOH/i-
PrOH were unsuccessful.  Tetrapeptide 2-1 was isolated as a white solid contaminated with 0.5 
equiv of isopropanol (22.3 mg, 21%, major component of a mixture in < 90% purity by NMR 
analysis): 1H NMR (CD3OD, 400 MHz) δ 8.50 (t, 1 H, J = 5.6 Hz), 8.37 (d, 0.6 H, J = 7.2 Hz), 
8.18 (d, 1 H, J = 8.0 Hz), 7.75 (d, 2 H, J = 8.0 Hz), 7.35 (d, 2 H, J = 8.0 Hz), 7.29 – 7.21 (m, 14 
H), 6.69 (s, 1 H), 5.01, 4.95 (AB, 2 H, J = 12.4 Hz), 4.74 – 4.66 (m, 1 H), 4.48 – 4.40 (m, 1 H), 
4.40 – 4.31 (m, 4 H), 4.24 (d, 1 H, J = 16.4 Hz), 4.01 (d, 1 H, J = 16.4 Hz), 3.78 – 3.70 (m, 1 H), 
3.23 (dd, 1 H, J = 13.6, 3.6 Hz), 2.89 (dd, 1 H, J = 13.6, 10.0 Hz), 2.29 (t, 2 H, J = 6.8 Hz), 2.17 
– 2.13 (m, 1 H), 1.96 – 1.87 (m, 4 H), 1.81 – 1.74 (m, 3 H), 1.65 – 1.50 (m, 3 H). 
Characteristic peaks of the impurity: 7.47 (d, 0.4 H, J = 8.4 Hz), 6.76 (s, 0.15 H); Peaks 
corresponding to isopropanol: 3.92 (sept., 1 H, J = 6.0 Hz), 1.14 (d, 6 H, J = 6.0 Hz). 
13C NMR (CD3OD, 100 MHz) δ 177.9, 175.3, 173.8, 172.8, 171.4, 158.3, 156.3, 142.2, 
139.8, 138.1, 131.1, 129.5, 129.1, 128.6, 128.4, 128.2, 126.5, 123.1, 67.6, 57.5, 54.6, 53.8, 53.7, 
51.7, 44.0, 38.8, 32.5, 32.1, 28.7, 28.6, 27.8. 
Peaks corresponding to isopropanol: 64.7, 25.2. 
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LC/MS (30 → 100% MeCN in water with 5% MeOH, ESI+) m/z (rel intensity) Rt = 5.85 
min.: 816.4 ([M + H]+, 30), 836.6 ([M + Na]+, 100); Characteristic peak of the impurity: Rt = 
5.99 min.: 860 (100). 
HRMS (ESI) m/z calcd for C40H45N7O10SNa [M + Na] 838.2846, found 838.2896. 
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CbzHN-(TDA)Tyr-(2-amido-ε-lactam)-Gly-Glu-NHBn (2-2).  A solution of methyl 
ester 2-42 (49.9 mg, 0.0964 mmol) in THF (1.0 mL) at 0 °C was treated with 0.2 N LiOH (1.0 
mL, 2.1 mmol, 2 equiv), warmed to room temperature, and stirred for 1.5 h. The reaction mixture 
was then acidified with 0.1 N HCl (2.5 mL) and extracted with EtOAc (3 x 4 mL). The combined 
organic layers were washed with brine, dried (MgSO4), filtered and condensed. The residue was 
isolated as a mixture of diastereomers on the thiadiazine ring and taken on without further 
purification.  A solution of crude the crude acid (assuming 100%), amine 2-30 (74.7 mg, 0.116 
mmol, 1.2 equiv) and DIPEA (0.032 mL, 0.19 mmol, 2 equiv) in DMF (1.0 mL) at 0 °C was 
treated with T3P (0.69 mL, 0.12 mmol, 1.2 equiv), warmed to room temperature, and stirred for 
8 h.  The reaction was monitored by LCMS.  The reaction mixture was concentrated under 
vacuum and taken on without further purification. A suspension of crude 2-46 (assuming 100%) 
and triethylsilane (0.021 mL, 0.13 mmol, 1.3 equiv) in CH2Cl2 (0.8 mL) was treated with TFA 
(0.2 mL) and stirred at room temperature for 3 h. The suspension was condensed under a stream 
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of air.  The residue was partially purified by reverse-phase HPLC (30 – 80% acetonitrile in 
water).  Attempts at further purification by recrystallization using methanol/water, 
methanol/CH2Cl2, methanol/ethyl acetate, methanol/ethyl ether, and methanol/isopropanol were 
unsuccessful.  Tetrapeptide 2-2 was isolated as a white solid contaminated with 0.2 equiv of 
isopropanol (12.0 mg, 8%, major component of a mixture in < 90% purity by NMR analysis): 
FT-IR (ATR) 3062, 3030, 2950, 1727, 1689, 1539, 1256; 1H NMR (CD3OD, 400 MHz) δ 7.58 
(d, 1 H, J = 2.0 Hz), 7.33 – 7.15 (m, 14 H), 5.42 (s, 1 H), 5.01 – 4.95 (m, 2 H), 4.71 (d, 1 H, J = 
11.2 Hz), 4.41 – 4.30 (m, 4 H), 4.22 (d, 1 H, J = 16.4 Hz), 4.03 – 3.90 (m, 2 H) (partially 
obscured by isopropanol), 3.76 (dd, 1 H, J = 14.8, 12.0 Hz), 3.13 (dd, 1 H, J = 13.6, 4.0 Hz), 
2.90 – 2.80 (m, 1 H), 2.31 – 2.20 (m, 2 H), 2.17 –  2.06 (m, 1 H), 2.00 – 1.68 (m, 5 H), 1.65 – 
1.50 (m, 2 H), 1.02 (t, 1.5 H, J = 7.2 Hz), 1.01 (t, 1.5 H, J = 7.2 Hz). 
Characteristic peaks of the impurity: 5.42 (s, 0.7 H), 2.64 (s, 0.7 H), 0.89 – 0.84 (m, 0.6 
H); Peaks corresponding to isopropanol: 3.92 (sept., 1 H, J = 6.0 Hz), 1.14 (d, 6 H, J = 6.0 Hz). 
 13C NMR (CD3OD, 100 MHz) δ 177.9, 175.3, 173.7, 173.1, 171.4, 167.9, 158.3, 141.8, 
139.8, 139.1, 138.0, 130.1, 129.5, 129.5, 129.2, 129.0, 128.7, 128.4, 128.2, 67.7, 61.2, 59.5, 57.8, 
54.6, 53.8, 53.6, 51.7, 44.0, 40.4, 38.4, 32.5, 32.2, 28.8, 28.6, 27.8, 14.5. 
Peaks corresponding to isopropanol: 64.7, 25.2. 
 LC/MS (30 → 100% MeCN in water with 5% MeOH, ESI+) m/z (rel intensity) Rt = 6.11 
min.: 889.4 ([M + H]+, 30), 911.5 ([M + Na]+, 100); Characteristic peaks of the impurity: Rt = 
6.38 min.: 943 (100) 
HRMS (ESI) m/z calcd for C43H52N8O11SNa [M + Na] 911.3374, found 911.3351. 
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